Here are 1-3 brief analogies for Rocket One (RKTO):

• Imagine a startup version of Moderna, focused on researching and developing many different experimental drugs that are still years away from being sold.

• It's like an early-stage biotech firm building a diverse drug pipeline, much like Amgen or Gilead were in their infancy, before they had any approved products on the market.

Major products of Rocket One (RKTO) are:

• HT-001: A topical formulation for treating rash and skin disorders associated with tyrosine kinase epidermal growth factor receptor inhibitor therapy.
• HT-KIT: A therapeutic compound developed to treat mast-cell derived cancers and anaphylaxis.
• HT-ALZ: A treatment and/or prevention therapy for Alzheimer's or other neuroinflammatory diseases.
• HT-003: A therapeutic compound aimed at treating inflammatory bowel diseases, as well as acne and psoriasis.
• HT-004: A therapy designed for the treatment of asthma and allergies using inhalational administration.
• HT-006: A treatment for lung diseases resulting from bacterial infections.
• HT-002: A novel peptide being developed for treating COVID-19.
• BioLexa Platform: A proprietary, patented drug compound platform in Phase I clinical trial for the treatment of eczema.
• HT-005: A therapeutic compound under development for treating patients with lupus.

Robb Knie, Chief Executive Officer

Robb Knie has served as President and Chief Executive Officer and as a director of Hoth Therapeutics (now Rocket One Inc.) since May 2017. He co-founded Hoth Therapeutics in 2017. He also served as the company's principal financial and accounting officer from June 2018 until March 2019. Since October 15, 2020, Mr. Knie has served as the Chief Executive Officer, Chief Financial Officer, and Chairman of the Board of FoxWayne Enterprises Acquisition Corp. (Nasdaq: FOXW). Furthermore, he served as the President of Lifeline Industries Inc. since its inception in 1995, and from 2002 to 2010, he was a Semiconductor Analyst for PAW Partners.

David S. Briones, Chief Financial Officer

David S. Briones serves as the Chief Financial Officer and Principal Accounting Officer of Rocket One Inc. (formerly Hoth Therapeutics). He is the founder and managing member of Brio Financial, bringing over fifteen years of public accounting and executive-level experience. Mr. Briones consults with various public companies on financial reporting, internal control development and evaluation, budgeting, and forecasting. He has specialized in representing private companies as an outsourced CFO/Financial reporting specialist through various stages of becoming a public company, including self-filings, reverse mergers, or traditional initial public offerings. Before founding Brio, Mr. Briones managed the Public Company and Hedge Fund practices at Bartolomei Pucciarelli, LLC, where he performed audit services and consulted clients on complex accounting principles. He was also an auditor with PricewaterhouseCoopers LLP in New York, specializing in the financial services group and working on initial public offerings for MONY Group, Prudential Financial, and MetLife.

Wayne D. Linsley, Director

Wayne D. Linsley has served as a director of Rocket One Inc. (formerly Hoth Therapeutics) since April 2020. He has over 40 years of experience in business management, encompassing a wide range of skills including sales and sales management, finance for both public and private companies, accounting, audit support, and financial reporting. From 2009 to September 2021, he worked for a financial reporting firm that collaborates with publicly traded companies, giving him extensive knowledge of financial statements, MD&A, and SEC Filings (such as 10-K, 10-Q, and 8-K). Since January 2020, Mr. Linsley has also served as a member of the board of directors of Uppercut Brands, Inc.

Chris Camarra, Director

Chris Camarra has served as a director of Rocket One Inc. (formerly Hoth Therapeutics) since May 2025. He has previously served as the Executive Vice President, Communications of TC BioPharm Limited (Nasdaq: TCBP), a clinical-stage biopharmaceutical company, since January 2022. Since 2010, he has been the President of CMC Ventures, LLC, a strategic communications firm. His prior roles include serving as a Partner at Capital Markets Group, LLC, Investor Relations Manager at Atari, and Financial Managing Associate at EY. From 2021 through 2024, Mr. Camarra also served as a member of the board of 3DX Industries Inc., a precision manufacturing company.

Key Business Risks for Rocket One (RKTO)

1. Clinical Trial Failure and Regulatory Approval Risk

   As a clinical-stage biopharmaceutical company, Rocket One (Hoth Therapeutics, Inc.) faces significant risk related to the successful development and regulatory approval of its pipeline of drug candidates. The company is involved in the development of numerous therapies, including HT-001, HT-KIT, HT-ALZ, HT-003, HT-004, HT-006, HT-002, BioLexa Platform, and HT-005, some of which are in Phase I clinical trials. The failure of any of these candidates in clinical trials, or the inability to obtain necessary regulatory approvals, could have a material adverse effect on the company's business, financial condition, and results of operations.

2. Intellectual Property and Licensing Risk

   Rocket One's business model relies heavily on license agreements with various institutions and companies, including the George Washington University, the University of Maryland, Isoprene Pharmaceuticals, Inc., the North Carolina State University, Chelexa BioSciences, Inc., Zylö Therapeutics, Inc., and the University of Cincinnati. Additionally, it has a research collaboration agreement with Weill Cornell Medicine. The success and longevity of these agreements, as well as the ability to protect its proprietary BioLexa Platform and other intellectual property, are critical. Any issues with these licenses, intellectual property disputes, or the inability to maintain or obtain new intellectual property rights, could significantly harm the company's prospects.

Here are the addressable market sizes for Rocket One's (RKTO) main products or services:

• HT-001 (Rash and skin disorders associated with tyrosine kinase epidermal growth factor receptor inhibitor therapy): The 7 major markets (United States, EU4, United Kingdom, and Japan) for EGFR inhibitors-induced skin disorders are expected to exhibit a compound annual growth rate (CAGR) of 17.89% during 2023-2034. The United States held the largest market share for this condition in 2023.
• HT-KIT (Mast-cell derived cancers): null
• HT-KIT (Anaphylaxis): The global anaphylaxis treatment market was valued at approximately USD 3.72 billion in 2025 and is projected to reach USD 7.95 billion by 2034. North America was the largest regional market for anaphylaxis in 2025.
• HT-ALZ (Alzheimer's or other neuroinflammatory diseases):
  • Alzheimer's Disease: The global Alzheimer's disease market is estimated to grow from USD 11.3 billion in 2024 to USD 12.4 billion in 2025 and USD 29.4 billion by 2035. North America dominated the Alzheimer's therapeutics market in 2022.
  • Neuroinflammatory Diseases: The global neuroinflammation market revenue was valued at USD 8.60 billion in 2025 and is expected to attain around USD 23.81 billion by 2035. North America led the neuroinflammation market in 2025 with a 40% share.
• HT-003 (Inflammatory bowel diseases): The global inflammatory bowel disease (IBD) treatment market size was estimated at USD 26.55 billion in 2023 and increased to USD 29.57 billion in 2024. North America accounted for approximately 41.02% of the market share in 2023.
• HT-003 (Acne): The global acne treatment market size is calculated at USD 10.90 billion in 2025 and is predicted to increase to approximately USD 17.76 billion by 2035. North America dominated the acne treatment market in 2025.
• HT-003 (Psoriasis): The global psoriasis treatment market size was valued at USD 29.15 billion in 2025 and is projected to grow to USD 72.99 billion by 2034. North America dominated the psoriasis treatment market with a market share of 74.83% in 2025.
• HT-004 (Asthma): The global asthma treatment market size is set to grow from USD 28.55 billion in 2025 to USD 38.57 billion by 2034. North America dominated the global market in 2024.
• HT-004 (Allergies - general treatment): The global allergy treatment market size was valued at USD 34.57 billion in 2024 and is projected to reach USD 64.65 billion by 2033. North America is expected to lead the global allergy treatment market with a 39% share in 2026.
• HT-006 (Lung diseases resulting from bacterial infections): null
• HT-002 (COVID-19): The global COVID-19 Therapeutics Market was valued at USD 42.47 billion in 2025 and is expected to reach USD 112.97 billion by 2034. North America is leading the COVID-19 Therapeutics Market.
• BioLexa Platform (Eczema): The global atopic eczema treatment market size was worth around USD 19.73 billion in 2024 and is predicted to grow to around USD 51.26 billion by 2034. North America was the largest region in the eczema market in 2025.
• HT-005 (Lupus): The global Lupus Market size was valued at USD 3,971.53 million in 2024, and the market is projected to grow to USD 11,699.42 million by 2035. North America dominated the global systemic lupus erythematosus market in 2023.

For Rocket One (symbol: RKTO), the expected drivers of future revenue growth over the next 2-3 years are primarily linked to its recent strategic pivot to the orbital economy, alongside the continued development of its biotechnology assets under a subsidiary.

1. Development and Commercialization of Nanomagnetic AI Chip Technology: Rocket One, formerly Hoth Therapeutics, Inc., has strategically refocused on the orbital economy. The company holds exclusive rights to a next-generation nanomagnetic AI chip architecture designed for ultra-low-power, radiation-tolerant computing, specifically for satellites, defense platforms, and space-based AI systems. The successful development, testing, and eventual commercialization of this technology are expected to be a primary revenue driver.
2. Securing Contracts and Expanding Market Penetration in the Space and Defense Sectors: A key driver will be the company's ability to secure contracts for its AI chip technology within the burgeoning orbital economy. This includes engaging with customers in the satellite, defense, and broader space-based AI system markets, leading to market adoption and expansion.
3. Advancement and Potential Commercialization of Key Biotechnology Assets: Although the company's main focus has shifted, its legacy biotechnology programs will continue under a wholly-owned subsidiary, now named Rocket One.0 Inc. Future revenue growth can be driven by the advancement of its clinical-stage pipeline, including HT-001 (Phase II for chemotherapy-induced skin rash), HT-KIT (which has received orphan drug designation for systemic mastocytosis and is nearing IND submission), and HT-ALZ (for Alzheimer's and neuroinflammatory diseases). Successful progression through clinical trials and eventual market approval and sales of these therapies would contribute to revenue.

Share Issuance

• In April 2026, Hoth Therapeutics (now Rocket One Inc.) completed a registered direct offering of 2,857,144 shares of common stock at $0.70 per share, generating approximately $2.0 million in gross proceeds, and concurrently issued unregistered warrants to purchase an equal number of shares.
• The company increased its at-the-market (ATM) sales agreement capacity by an additional $2,661,176 of common stock in May 2026, having previously sold 6,824,327 shares for approximately $6.6 million under the agreement.
• Hoth Therapeutics issued over 7.4 million more common shares in 2025 compared to 2024, primarily to raise capital, which resulted in dilution for existing shareholders.

Inbound Investments

• Hoth Therapeutics secured approximately $2.0 million in gross proceeds from a registered direct offering and concurrent private placement of warrants in April 2026.
• The company raised over $9.3 million in financing activities during 2025, largely through the sale of its stock.

Outbound Investments

• In April 2026, Hoth Therapeutics formed Rocket One Inc. as a wholly-owned subsidiary, intending for it to acquire, own, and operate space-industry assets such as nano rocket systems for nanosatellite deployment.
• The company obtained exclusive license rights to nanomagnetic AI chip technology designed for ultra-low-power, radiation-tolerant computing, signaling a strategic pivot towards the space and defense industry.
• Hoth Therapeutics invested $300,000 in crypto assets during 2025.

Capital Expenditures

• Hoth Therapeutics reported research and development expenses of approximately $5.9 million in 2025 and about $1.5 million in the first quarter of 2026, primarily focused on its biopharmaceutical pipeline.
• Substantial additional capital will be required to fabricate, test, and qualify the newly licensed nanomagnetic AI chip technologies for use in space environments.